MP19-06 ANTIBIOTIC USE, BEST PRACTICE STATEMENT ADHERENCE, AND UTI RATE FOR INTRADETRUSOR ONABOTULINUMTOXIN A INJECTION FOR OVERACTIVE BLADDER: A MULTI-INSTITUTIONAL COLLABORATION FROM THE SUFU RESEARCH NETWORK

Abstract

You have accessJournal of UrologyCME1 Apr 2023MP19-06 ANTIBIOTIC USE, BEST PRACTICE STATEMENT ADHERENCE, AND UTI RATE FOR INTRADETRUSOR ONABOTULINUMTOXIN A INJECTION FOR OVERACTIVE BLADDER: A MULTI-INSTITUTIONAL COLLABORATION FROM THE SUFU RESEARCH NETWORK Katherine Shapiro, Monica van Til, Stephanie Daignault-Newton, Giulia Lane, Ariana Smith, Una Lee, Anne Suskind, Jennifer Anger, Doreen Chung, W. Stuart Reynolds, Anne Cameron, Christopher Tenggardjaja, Priya Padmanabhan, Benjamin Brucker, and Sufu Research Network Katherine ShapiroKatherine Shapiro More articles by this author , Monica van TilMonica van Til More articles by this author , Stephanie Daignault-NewtonStephanie Daignault-Newton More articles by this author , Giulia LaneGiulia Lane More articles by this author , Ariana SmithAriana Smith More articles by this author , Una LeeUna Lee More articles by this author , Anne SuskindAnne Suskind More articles by this author , Jennifer AngerJennifer Anger More articles by this author , Doreen ChungDoreen Chung More articles by this author , W. Stuart ReynoldsW. Stuart Reynolds More articles by this author , Anne CameronAnne Cameron More articles by this author , Christopher TenggardjajaChristopher Tenggardjaja More articles by this author , Priya PadmanabhanPriya Padmanabhan More articles by this author , Benjamin BruckerBenjamin Brucker More articles by this author , and Sufu Research Network More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000003244.06AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Onabotulinumtoxin A (BTX-A) is a well-established treatment for overactive bladder (OAB). The American Urological Association (AUA) 2008 Antibiotic Best Practice Statement recommended trimethoprim-sulfamethoxazole or fluoroquinolone for cystoscopy with manipulation. The aim of the study was to evaluate concordance with antibiotic best practices at the time of BTX-A injection and urinary tract infection (UTI) rates based on antibiotic regimen. METHODS: We included men and women undergoing first-time BTX-A injection for idiopathic OAB with 100 units in 2016 within the SUFU Research Network multi-institutional retrospective database. Patients on suppressive antibiotics were excluded. The primary outcome was concordance of periprocedural antibiotic use with the AUA 2008 Best Practice Statement. As a secondary outcome we compared the incidence of UTI at 15 days and 30 days after BTX-A among women. 15 days was used as a cutoff for a UTI attributed to BTX-A injection procedure, whereas a UTI within 30 days was considered a chronic effect of BTX-A. We assumed that patients who were not seen in the first 15 days did not have a UTI within 15 days. Fisher’s exact tests were applied for categorical variables. RESULTS: Of the cohort of 216 patients (175 women, 41 men) undergoing BTX-A, 24 different periprocedural antibiotic regimens were utilized. Among patients who had in-office visits within 15 days of BTX-A, 87% received periprocedural antibiotics and 47% received best practice statement-concordant antibiotics. There was no significant difference in UTI events between patients who received any antibiotics and those that did not at 15 day follow up (N=173, 6% vs 9%, p=0.4). Of patients who received antibiotics, UTI rates did not vary significantly depending on concordance with recommendations or not (N=133, 5% vs 7%, p=0.7). 81% of the 216 patients with 30-day follow up received periprocedural antibiotics. Of those, 47% received best practice statement-concordant antibiotics. At 30 days, there was no significant difference in UTI events based on antibiotic use (N=173, 11% antibiotics vs 16% no antibiotics, p=0.5) or best practice statement concordance or not 8% vs 16% (N=133, p=0.13). CONCLUSIONS: This retrospective multi-institutional study demonstrates that antibiotic regimens and adherence to the AUA Best Practice Statement was variable among providers and that UTI rates at 15 or 30 days following BTX-A did not vary significantly regardless of antibiotic use or alignment with best practices. Source of Funding: SUFU Research Network © 2023 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 209Issue Supplement 4April 2023Page: e266 Advertisement Copyright & Permissions© 2023 by American Urological Association Education and Research, Inc.MetricsAuthor Information Katherine Shapiro More articles by this author Monica van Til More articles by this author Stephanie Daignault-Newton More articles by this author Giulia Lane More articles by this author Ariana Smith More articles by this author Una Lee More articles by this author Anne Suskind More articles by this author Jennifer Anger More articles by this author Doreen Chung More articles by this author W. Stuart Reynolds More articles by this author Anne Cameron More articles by this author Christopher Tenggardjaja More articles by this author Priya Padmanabhan More articles by this author Benjamin Brucker More articles by this author Sufu Research Network More articles by this author Expand All Advertisement PDF downloadLoading ...